Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Startups channel feed
Nancy Stagliano bags another $45M for True North’s rare disease R&D
9 years ago
Financing
Armed antibody player ADC lands a $105M mega-round to back pipeline construction
9 years ago
Financing
UK startup tackles hot neoantigen field in cancer drugs
9 years ago
Financing
UCSF scientist rolls out a new blueprint for programming T cells, the 2.0 way
9 years ago
The next Sage? Shkreli partner Ligand puts together another sweet startup package deal for Seelos
9 years ago
Pharma
The next checkpoints? Immuno-oncology upstart looks to find new ways to unleash T cells
9 years ago
Financing
The gamma delta T cell gambit inspires a small London biotech startup with big ideas
9 years ago
Third Rock ramps up a $57M upstart focusing on proteins in motion
9 years ago
Financing
Protocols: BeiGene signs up Medivation’s Amy Peterson as its new CMO; Acne drug developer files for $60M IPO
9 years ago
R&D
News Briefing
Denali grabs another megaround while inking a flurry of neurodegeneration R&D pacts
9 years ago
Financing
Ex-Allergan CEO David Pyott backs a biotech startup alongside Takeda, PhI trial set to launch
9 years ago
People
R&D
Ex-Biogen exec Steve Holtzman hears the call of Third Rock’s ambitious Decibel
9 years ago
People
$42M in, Flagship startups merge into one immuno-microbiome platform with multiple targets
9 years ago
R&D
First page
Previous page
71
72
73
74
